View More Recent Stories
-
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
-
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
-
Hemostemix Closes Private Placement of $469,366
-
Hemostemix Presents at TERMIS 2025, Freiburg, Germany
-
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
-
Hemostemix at Invest Stuttgart
-
Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio
-
Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial
-
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
-
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
-
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies
-
Hemostemix Licenses CytoImmune's BioReactor Technologies
-
Hemostemix Provides Corporate Update
-
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification
-
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
-
Hemostemix Up-lists to TradeGateExchange in Germany
-
Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico
-
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
